Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (36)

2024

  1. Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators

    Journal of Prevention of Alzheimer's Disease

2022

  1. Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APPswe Alzheimer’s Disease Mouse Model

    International Journal of Molecular Sciences, Vol. 23, Núm. 7

2021

  1. Corticosteroid-binding-globulin (CBG)deficient mice show high pY216-GSK3β and phosphorylated-Tau levels in the hippocampus

    PLoS ONE, Vol. 16, Núm. 2 February

2020

  1. Smelling the Dark Proteome: Functional Characterization of PITH Domain-Containing Protein 1 (C1orf128) in Olfactory Metabolism

    Journal of Proteome Research, Vol. 19, Núm. 12, pp. 4826-4843

2019

  1. Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson's disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model

    Frontiers in Immunology, Vol. 10, Núm. MAY

2018

  1. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

    Biochemical Pharmacology, Vol. 157, pp. 67-84

  2. Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice

    Neuropsychopharmacology, Vol. 42, Núm. 2, pp. 524-539

  2. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

  3. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

    Neuropharmacology, Vol. 113, pp. 110-123

2016

  1. Limited unfolded protein response and inflammation in neuroserpinopathy

    Journal of Neuropathology and Experimental Neurology, Vol. 75, Núm. 2, pp. 121-133

  2. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 3, Núm. 3

  3. Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors

    Molecular Neurobiology, Vol. 53, Núm. 4, pp. 2312-2319

  4. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415

2015

  1. Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease

    Clinical Epigenetics, Vol. 7, Núm. 1

  2. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

    Neuropathology and Applied Neurobiology, Vol. 41, Núm. 4, pp. 471-482

  3. Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins

    Trends in Biochemical Sciences

2014

  1. GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells

    Hippocampus, Vol. 24, Núm. 7, pp. 733-739

  2. Phosphodiesterase inhibition in cognitive decline

    Journal of Alzheimer's Disease, Vol. 42, pp. S561-S573

  3. Synthesis and evaluation of 13N-labelled azo compounds for β-amyloid imaging in mice

    Molecular Imaging and Biology, Vol. 16, Núm. 4, pp. 538-549